{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:55:48Z","timestamp":1790207748513,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple drugs targeting the human epidermal growth factor receptor-2 (HER2) have shown clinical activity in gastrointestinal (GI) cancers. How to best integrate these various options in clinical practice alongside conventional therapy, however, is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We assessed the clinical outcomes of 103 patients with advanced HER2-altered GI malignancies who received\u2009\u2265\u20091 line of anti-HER2 therapy at our institution between 2010 and 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Next-generation sequencing (NGS) detected an\n                      <jats:italic>ERBB2<\/jats:italic>\n                      amplification in 66% (27\/41) of tumors that were HER2\u2009+\u2009by IHC\/ISH. Conversely, all patients with\n                      <jats:italic>ERBB2<\/jats:italic>\n                      amplification were HER2\u2009+\u2009by IHC. In the second-line and beyond, trastuzumab plus pertuzumab had the longest median time to treatment discontinuation (7.9 months), followed by trastuzumab deruxtecan (5.0 months). Among 25 patients who received\u2009\u2265\u20092 anti-HER2 agents, 24% had more durable clinical benefit to their second-line HER2 therapy compared to their first, as measured by the growth modulation index.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Multimodal HER2 testing is needed to accurately identify candidates for HER2-targeted treatment, as NGS alone misses a significant proportion of cases. Patients who develop resistance to one anti-HER2 agent may still achieve benefit from subsequent HER2-directed regimens. Early and serial treatment with HER2-directed agents should be considered for patients with HER2\u2009+\u2009GI cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16309-3","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:06:34Z","timestamp":1781064394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical benefit of various HER2-directed regimens in gastrointestinal malignancies: a retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Vishesh","family":"Khanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Vadde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Solomon","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler P.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagufta","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Heestand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Holden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis R.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipika","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"16309_CR1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783\u201392. https:\/\/doi.org\/10.1056\/NEJM200103153441101.","journal-title":"N Engl J Med"},{"key":"16309_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707\u201312. https:\/\/doi.org\/10.1126\/science.2470152.","journal-title":"Science"},{"key":"16309_CR3","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","volume":"21","author":"J Yoon","year":"2024","unstructured":"Yoon J, Oh D-Y. HER2-targeted therapies beyond breast cancer - an update. Nat Rev Clin Oncol. 2024;21:675\u2013700. https:\/\/doi.org\/10.1038\/s41571-024-00924-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"16309_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","volume":"24","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Cercek A, Siena S, Andr\u00e9 T, Ng K, Cutsem EV, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023;24:496\u2013508. https:\/\/doi.org\/10.1016\/S1470-2045(23)00150-X.","journal-title":"Lancet Oncol"},{"key":"16309_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, Cutsem EV, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"key":"16309_CR6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","volume":"17","author":"A Sartore-Bianchi","year":"2016","unstructured":"Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)00150-9.","journal-title":"Lancet Oncol"},{"key":"16309_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.22.02636","volume":"42","author":"CJ Sweeney","year":"2024","unstructured":"Sweeney CJ, Hainsworth JD, Bose R, Burris HA, Kurzrock R, Swanton C, et al. MyPathway human epidermal growth factor receptor 2 basket study: pertuzumab\u2009+\u2009trastuzumab treatment of a tissue-agnostic cohort of patients with human epidermal growth factor receptor 2\u2013altered advanced solid tumors. JCO. 2024;42:258\u201365. https:\/\/doi.org\/10.1200\/JCO.22.02636.","journal-title":"JCO"},{"key":"16309_CR8","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2004413.","journal-title":"N Engl J Med"},{"key":"16309_CR9","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","volume":"14","author":"T Yoshino","year":"2023","unstructured":"Yoshino T, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun. 2023;14:3332. https:\/\/doi.org\/10.1038\/s41467-023-38032-4.","journal-title":"Nat Commun"},{"key":"16309_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s12935-022-02761-1","volume":"22","author":"L Morsberger","year":"2022","unstructured":"Morsberger L, Pallavajjala A, Long P, Hardy M, Park R, Parish R, et al. HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry. Cancer Cell Int. 2022;22:350. https:\/\/doi.org\/10.1186\/s12935-022-02761-1.","journal-title":"Cancer Cell Int"},{"key":"16309_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jmoldx.2016.09.010","volume":"19","author":"DS Ross","year":"2017","unstructured":"Ross DS, Zehir A, Cheng DT, Benayed R, Nafa K, Hechtman JF, et al. Next-generation assessment of human epithelial growth factor receptor 2 (ERBB2) amplification status. J Mol Diagn. 2017;19:244\u201354. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.09.010.","journal-title":"J Mol Diagn"},{"key":"16309_CR12","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.2217\/fon-2021-0203","volume":"17","author":"SM Stein","year":"2021","unstructured":"Stein SM, Snider J, Ali SM, Miksad RA, Alexander BM, Castellanos E, et al. Real-world association of HER2\/ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. Future Oncol. 2021;17:4101\u201314. https:\/\/doi.org\/10.2217\/fon-2021-0203.","journal-title":"Future Oncol"},{"key":"16309_CR13","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.3748\/wjg.v22.i19.4619","volume":"22","author":"LF Abrahao-Machado","year":"2016","unstructured":"Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. World J Gastroenterol. 2016;22:4619\u201325. https:\/\/doi.org\/10.3748\/wjg.v22.i19.4619.","journal-title":"World J Gastroenterol"},{"key":"16309_CR14","doi-asserted-by":"publisher","first-page":"v183","DOI":"10.1093\/annonc\/mdz244.047","volume":"30","author":"A Italiano","year":"2019","unstructured":"Italiano A, Nanda S, Keating K, Childs BH, Fellous M, Drilon A, et al. Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients. Ann Oncol. 2019;30:v183\u20134. https:\/\/doi.org\/10.1093\/annonc\/mdz244.047.","journal-title":"Ann Oncol"},{"key":"16309_CR15","doi-asserted-by":"publisher","unstructured":"Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D\u2019Andre S, et al. Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: results from the TAPUR study. JCO Precis Oncol. 2022;e2200306. https:\/\/doi.org\/10.1200\/PO.22.00306.","DOI":"10.1200\/PO.22.00306"},{"key":"16309_CR16","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","volume":"24","author":"JJ Harding","year":"2023","unstructured":"Harding JJ, Fan J, Oh D-Y, Choi HJ, Kim JW, Chang H-M, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24:772\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(23)00242-5.","journal-title":"Lancet Oncol"},{"key":"16309_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.molonc.2015.09.002","volume":"10","author":"P Nuciforo","year":"2016","unstructured":"Nuciforo P, Thyparambil S, Aura C, Garrido-Castro A, Vilaro M, Peg V, et al. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Mol Oncol. 2016;10:138\u201347. https:\/\/doi.org\/10.1016\/j.molonc.2015.09.002.","journal-title":"Mol Oncol"},{"key":"16309_CR18","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1158\/1078-0432.CCR-18-3389","volume":"25","author":"G Siravegna","year":"2019","unstructured":"Siravegna G, Sartore-Bianchi A, Nagy RJ, Raghav K, Odegaard JI, Lanman RB, et al. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin Cancer Res. 2019;25:3046\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3389.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16309-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16309-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16309-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T02:59:02Z","timestamp":1786676342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16309-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16309"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16309-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted with the approval of the Stanford University Institutional Review Board (protocol number: IRB-67569). As the study involved retrospective review of patient information solely by authorized study personnel, it was deemed to involve no more than a minimal risk to patient privacy; thus, the need for participant consent was waived. This study was conducted in accordance with the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, applicable International Conference on Harmonization Good Clinical Practice Guidelines, and applicable laws and regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.R.C. has received consulting fees from Astra Zeneca and was previously a consultant to Foundation Medicine. G.M.H. reports family employment and equity interest in Genentech-Roche. C.T.C. has received research grants (to his institution) from the following: Cholangiocarcinoma Foundation, ADC Therapeutics, Oric Pharmaceuticals, Seattle Genetics, Rain Therapeutics, Kinnate, Gilead, Mersana Therapeutics, Riboscience, Takeda, Palleon, Merus, Revolution Medicines, Tango Therapeutics, and Genentech-Roche, and has received consulting fees from Boxer Capital and Guidepoint Global Advisors. L.G. has received contracted research grants (with her institution) from the following: Alyssum Therapeutics, Boehringer Ingelheim, Genentech, AstraZeneca, Cogent, Tyra Biosciences. She has received consulting fees from AbbVie, Agenus, AstraZeneca (DSMB), Boehringer Ingelheim, Compass Therapeutics, Exelixis, Kinnate Biopharma, Merck, Revolution Medicine, Relay Therapeutics, Servier, Surface Oncology, Taiho, TransThera Biosciences, Tyra Biosciences. The remaining authors report no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"983"}}